RT Journal
A1 Cook NR
T1 BIomarkers for prediction of cardiovascular events
JF JAMA
JO JAMA
YR 2009
FD November 18
VO 302
IS 19
SP 2089
OP 2090
DO 10.1001/jama.2009.1636
UL http://dx.doi.org/10.1001/jama.2009.1636
AB 
To the Editor: Dr Melander and colleagues1 suggested that gains in risk prediction using new biomarkers for cardiovascular disease are minimal using risk reclassification, a technique that can help determine whether new markers can change clinical decisions.2 In contrast to similar analyses using data from the Women's Health Study, the Physicians' Health Study, and the Framingham Heart Study, there was no improvement in risk stratification with new markers, including C-reactive protein (CRP).